Angle: Pharma firm’s share price plunges after missing market forecasts June 5, 2024 Angle also today announced a plan to raise about £8.5m through a combination of new share placements and subscriptions.
Astrazeneca swallows up Canada-based Fusion Pharmaceuticals in £1.5bn move June 5, 2024 Astrazeneca has completed its $2bn (£1.5bn) acquisition of Canada-based Fusion Pharmaceuticals, in a deal first announced in March.
GSK: How much could the Zantac lawsuits cost? June 3, 2024 Last month, Shore Capital analysts estimated that up to $30bn (£24bn) for litigation was already priced into GSK’s shares.
Boots: Profit surges at British icon as owner mulls £7bn London float May 29, 2024 Historic pharmacy chain Boots has reported a surge in its pre-tax profit for its latest financial year amid reports its owner is considering a £7bn float in London.
Astrazeneca to build huge new cancer drug plant in Singapore May 20, 2024 Astrazeneca has said it will invest $1.5bn (£1.2bn) to build a manufacturing facility in Singapore to produce antibody drug conjugates (ADCs), a next-generation cancer treatment.
Ozempic and Wegovy: What happens when a drug goes viral? May 18, 2024 Novo Nordisk's Wegovy and Ozempic have been heralded as the solution to the world's growing obesity problems. But when celebrities and influencers misuse them and start documenting their weight loss journeys online, should we take stock?
Haleon posts healthy first quarter update after UK job cuts May 1, 2024 Revenue at Haleon was up in the first quarter despite its announcement yesterday that it would cut over 400 jobs in the UK, as the consumer healthcare firm posted a quarterly update in line with expectations.
Drugmaker Indivior seeks shareholder approval to move primary listing from London to New York April 25, 2024 Opioid dependence treatment maker Indivior has confirmed a plan to move its primary stock market listing from London to New York this summer in yet another blow to the capital's beleaguered bourse.
Angle agrees deal with Astrazeneca for tech to kill cancer cells April 24, 2024 This is expected to be driven by an increase in the use of combination therapy for the treatment of drug-resistant cancers and the need for novel targeted medicines for cancer treatment.
AIM-listed biotech firms face crunch votes on London Stock Exchange exits April 14, 2024 Redx Pharma and C4X Discovery have scheduled general meetings this week to vote on proposals for delisting from the London Stock Exchange.